Changes in serum vitamin B₁₂ levels in patients with megaloblastic anaemia treated with folic acid

S. JOHNSON, S. P. SWAMINATHAN, AND S. J. BAKER
From the Christian Medical College Hospital, Vellore, South India

SYNOPSIS In 21 patients with megaloblastic anaemia associated with the tropical malabsorption syndrome serum vitamin B₁₂ levels have been measured serially before and during parenteral folic acid therapy.

In 11 patients there was a significant rise in serum B₁₂ levels, reaching a peak three to 17 days after starting the folic acid. In three of these cases, absorption of labelled B₁₂ was the same before and after the administration of folic acid. In two cases there was a fall in serum B₁₂ levels and in seven there was no change. In one case small amounts of folic acid produced no change in serum B₁₂ levels, whereas larger doses produced a prompt but transient rise.

A rise in the serum vitamin B₁₂ levels in patients treated with folic acid has been noticed by several workers (Narayanan, Shenoy, and Ramasarma, 1956, 1957; Narayanan, 1961; Mollin and Ross, 1957). It is the purpose of this communication to report further observations on the effect of folic acid therapy on the serum vitamin B₁₂ levels of patients with megaloblastic anaemia associated with the tropical malabsorption syndrome.

MATERIALS AND METHODS

Serum vitamin B₁₂ estimations were performed by the method of Ross, Hutner, and Bach (1957) using Euglena gracilis Z strain. Radioactive vitamin B₁₂ absorption tests were carried out by the faecal excretion method of Heine, Welch, Scharf, Meacham, and Prusoff (1952) using 1 µg. vitamin B₁₂ labelled with Co⁶⁰ (obtained from the Radiochemical Centre, Amersham, England) and carbamylcholine chloride as a stimulant to intrinsic factor secretion (Baker and Mollin, 1955).

Twenty-one patients suffering from the malabsorption syndrome or 'idiopathic tropical steatorrhoea' and associated megaloblastic anaemia (Baker 1957, 1958) were studied as hospital in-patients. In each case patients were kept on the same diet as they had been having before admission, the patients' relatives supplying their own food from home. In every case there was a control period of at least 10 days in hospital before any therapy was begun, and subsequently daily intramuscular injections of folic acid were given. In Cases 1 to 20, 15 mg. a day was given for 20 to 30 days. In Case 21, 0-2 mg. was given daily for 22 days and then the dose was increased to 15 mg. a day for 28 days. No other specific therapy was given during the course of the study. The serum vitamin B₁₂ levels in the plasma were estimated at regular intervals.

RESULTS

SERUM B₁₂ LEVELS The changes in the serum B₁₂ levels are shown in Fig. 1. In 11 patients (Fig. 1, Cases 1 to 11) there was a significant rise in serum B₁₂ levels reaching a maximum in three to 17 days. In Case 1 this rise in serum levels was sustained throughout the period of observation. Case 7 left hospital on the fourth day of folic acid therapy. In all the other cases the rise in serum levels was subsequently followed by a fall with a tendency to return to pre-treatment levels.

In two patients there was a slight fall (Fig. 1, Cases 12 and 13), and in seven patients there was no significant change in serum vitamin B₁₂ levels (Fig. 1, Cases 14 to 20).

In Case 21 there was no change in serum B₁₂ levels when a dose of 0-2 mg. of folic acid was given daily, but a transient rise was observed when the dose was increased to 15 mg. a day (Fig. 2).

VITAMIN B₁₂ ABSorption In three patients (Cases 1, 6, and 8) in whom folic acid produced a rise in serum B₁₂ levels, B₁₂ absorption before and after folic acid was measured. In each case B₁₂ absorption was defective, and there was no significant improvement following folic acid administration (Fig. 3).

HAEMATOLOGICAL RESPONSE In Cases 1 to 20 after the administration of folic acid the marrow reverted...
Changes in serum vitamin $B_{12}$ levels in patients with megaloblastic anaemia treated with folic acid

FIG. 1. Serum $B_{12}$ levels in $\mu$g./ml. in Cases 1 to 20 given daily injections of 15 mg. of folic acid from day 0 onwards.

to a normoblastic pattern and there was a reticulocytosis, but in many this was suboptimal, and in these cases the subsequent rise in red cells and haemoglobin was also suboptimal. There was no correlation between the haematological response and the degree of change in serum $B_{12}$ levels. In Case 21 there was no haematological response to 0.2 mg. of folic acid but on increasing the dose to 15 mg. there was a bone marrow response followed by a suboptimal rise in red cells and haemoglobin.
or haematological difference between the patients in whom there was a rise in $B_{12}$ levels and ones in which there was no rise, except that the mean pretreatment serum $B_{12}$ level was higher in the former group (98.5 μg./ml) than in the latter (77.3 μg./ml). However, Case 3, in which there was a rise in $B_{12}$ levels, had pre-treatment serum levels of 20 to 25 μg./ml, a level as low as any in the group which did not show a rise. Narayanan et al. (1957) have suggested that those with greater body stores are those more likely to show a rise in serum levels. It may well be that pre-treatment serum levels do not always accurately indicate the level of body stores, but at least one patient (Case 1) was known to have had a $B_{12}$ absorptive defect for five years and his body stores must therefore have been low; nevertheless he showed a prompt rise in serum levels after the administration of folic acid.

The maximum rise in serum vitamin $B_{12}$ levels observed ranged from 100 to 460 μg./ml. If we assume that the total plasma volume is 3 litres this means a total increase in the plasma $B_{12}$ of about 1.5 μg. This could come about either by an improved absorption of $B_{12}$ from the gastrointestinal tract or by an internal shift of vitamin $B_{12}$ from the tissue stores to the plasma.

The fact that in three cases the absorption of radioactive vitamin $B_{12}$ before and after the administration of folic acid was unchanged suggests that improved absorption is not the explanation for the rise in serum levels.

The initial rise in serum $B_{12}$ levels could be explained on the basis of mobilization of $B_{12}$ from ‘labile’ body stores, presumably in the liver, and the subsequent fall in serum levels occurring when these labile stores were exhausted. The patient described by Mollin and Ross (1957) did not show a subsequent fall in $B_{12}$ levels during the period of study. It may be that this patient’s body stores were high. Such an explanation, however, does not seem very likely in our Case 1, who had a long-standing absorptive defect.

Even in $B_{12}$-depleted individuals the amount of $B_{12}$ needed to raise serum levels will only be a small fraction of the total amount remaining in the body. One would therefore not be likely to be able to detect this change in body stores by currently available methods.

It is interesting that in Case 21 small doses of folic acid failed to cause any increase in serum $B_{12}$ levels, whereas larger doses caused a prompt though transient rise. This suggests that there may be a critical amount of folic acid needed to produce this effect.

Wilson and Pitney (1955) found that in monkeys fed on a folic acid-deficient diet the serum $B_{12}$ levels
Changes in serum vitamin \( \text{B}_{12} \) levels in patients with megaloblastic anaemia treated with folic acid fell, and in two out of three such animals given folic acid there was a rise in serum \( \text{B}_{12} \) levels followed by a fall. They suggested, without any direct evidence, that the folic acid deficiency depressed \( \text{B}_{12} \) absorption which was improved on giving folic acid.

Cox, Meynell, Gaddie, and Cooke (1959), in 13 patients with iron-deficiency anaemia and low serum \( \text{B}_{12} \) levels, found a rise in serum \( \text{B}_{12} \) following iron administration. The peak rise, however, in their cases was much later than in our patients given folic acid, and the mechanism involved may be quite different.

The changes in serum \( \text{B}_{12} \) levels after folic acid administration underline the difficulties in diagnosis which may occur when folic acid is given to patients before adequate investigations have been undertaken. The use of folic acid may convert a low serum \( \text{B}_{12} \) level, even in a patient with depleted \( \text{B}_{12} \) stores, into a normal or near normal serum level, thus masking the diagnosis. Further, random serum \( \text{B}_{12} \) estimations may be misleading in assessing the \( \text{B}_{12} \) status of an individual, unless the folic acid status of the patient is also known.

REFERENCES